Delayed re-endothelialization with rapamycin-coated stents is rescued by the addition of a glycogen synthase kinase-3 inhibitor

Cardiovascular Research

Volumn 86, Issue 2, 2010, Pages 338-345

  Ma, Xiaoli ^a   Hibbert, Benjamin ^a   Dhaliwal, Bharbhoor ^a   Seibert, Tara ^a   Chen, Yong Xiang ^a   Zhao, Xiaoling ^a   O'Brien, Edward R ^a  

^a UNIVERSITY OF OTTAWA HEART INSTITUTE   (Canada)

Author keywords

Endothelial progenitor cells; Re endothelialization; Restenosis; Stents

Indexed keywords

GLYCOGEN SYNTHASE KINASE 3 INHIBITOR; GLYCOGEN SYNTHASE KINASE 3BETA INHIBITOR; RAPAMYCIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BARE METAL STENT; BLOOD VESSEL REACTIVITY; CAROTID ARTERY; CELL ADHESION; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DRUG ELUTING STENT; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; IN VITRO STUDY; INTIMA; NONHUMAN; NORMAL HUMAN; PRIORITY JOURNAL; STEM CELL;

ANIMALS; CAROTID ARTERIES; CAROTID ARTERY DISEASES; CELL ADHESION; CELL PROLIFERATION; CELLS, CULTURED; DISEASE MODELS, ANIMAL; DRUG-ELUTING STENTS; ENDOTHELIAL CELLS; GLYCOGEN SYNTHASE KINASE 3; HUMANS; MALE; PROSTHESIS DESIGN; PROTEIN KINASE INHIBITORS; RABBITS; SIROLIMUS; STEM CELLS; TIME FACTORS;

EID: 77951668408     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvq047     Document Type: Article

References (44)

1. Zampetaki A, Kirton JP, Xu Q. Vascular repair by endothelial progenitor cells. Cardi-ovasc Res 2008;78:413-421. (Pubitemid 351769775)
2. Werner N, Junk S, Laufs U, Link A, Walenta K, Bohm M et al. Intravenous transfusion of endothelial progenitor cells reduces neointima formation after vascular injury. Circ Res 2003;93:e17-e24.
3. Urbich C, Dimmeler S. Endothelial progenitor cells: characterization and role in vascular biology. Circ Res 2004;95:343-353. (Pubitemid 39100452)
4. Serruys PW, Kutryk MJ, Ong AT, Coronary-artery stents. N Engl J Med 2006;354: 483-495.
5. Joner M, Finn AV, Farb A, Mont EK, Kolodgie FD, Ladich E et al. Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. J Am Coll Cardiol 2006;48:193-202. (Pubitemid 43929240)
6. Van BE, Tio FO, Chen D, Maillard L, Chen D, Kearney M et al. Passivation of metallic stents after arterial gene transfer of phVEGF165 inhibits thrombus formation and intimal thickening. J Am Coll Cardiol 1997;29:1371-1379. (Pubitemid 27201960)
7. Walter DH, Cejna M, az-Sandoval L, Willis S, Kirkwood L, Stratford PW et al. Local gene transfer of phVEGF-2 plasmid by gene-eluting stents: an alternative strategy for inhibition of restenosis. Circulation 2004;110:36-45. (Pubitemid 38885702)
8. Sato N, Meijer L, Skaltsounis L, Greengard P, Brivanlou AH. Maintenance of pluripo-tency in human and mouse embryonic stem cells through activation of Wnt signaling by a pharmacological GSK-3-specific inhibitor. Nat Med 2004;10:55-63. (Pubitemid 38524699)
9. Trowbridge JJ, Xenocostas A, Moon RT, Bhatia M. Glycogen synthase kinase-3 is an in vivo regulator of hematopoietic stem cell repopulation. Nat Med 2006;12:89-98. (Pubitemid 43050082)
10. Choi JH, Hur J, Yoon CH, Kim JH, Lee CS, Youn SW et al. Augmentation of therapeutic angiogenesis using genetically modified human endothelial progenitor cells with altered glycogen synthase kinase-3beta activity. J Biol Chem 2004;279: 49430-49438.
11. Hibbert B, Ma X, Pourdjabbar A, Holm E, Rayner K, Chen YX et al. Inhibition of endo-thelial progenitor cell glycogen synthase kinase-3fbetag results in attenuated neoin-tima formation and enhanced re-endothelialization after arterial injury. Cardiovasc Res 2009;83:16-23.
12. George J, Shmilovich H, Deutsch V, Miller H, Keren G, Roth A. Comparative analysis of methods for assessment of circulating endothelial progenitor cells. Tissue Eng 2006; 12:331-335. (Pubitemid 44772932)
13. Hibbert B, Chen YX, O'Brien ER. c-kit-immunopositive vascular progenitor cells populate human coronary in-stent restenosis but not primary atherosclerotic lesions. Am J Physiol Heart Circ Physiol 2004;287:H518-H524. (Pubitemid 38955279)
14. Hibbert B, Olsen S, O'Brien E. Involvement of progenitor cells in vascular repair. Trends Cardiovasc Med 2003;13:322-326. (Pubitemid 37338564)
15. Hirschi KK, Ingram DA, Yoder MC. Assessing identity, phenotype, and fate of endo-thelial progenitor cells. Arterioscler Thromb Vasc Biol 2008;28:1584-1595.
16. Chen YX, Ma X, Whitman S, O'Brien ER. Novel antiinflammatory vascular benefits of systemic and stent-based delivery of ethylisopropylamiloride. Circulation 2004;110: 3721-3726. (Pubitemid 39665263)
17. Bhat R, Xue Y, Berg S, Hellberg S, Ormo M, Nilsson Y et al. Structural insights and biological effects of glycogen synthase kinase 3-specific inhibitor AR-A014418. J Biol Chem 2003;278:45937-45945. (Pubitemid 37432740)
18. Klugherz BD, Llanos G, Lieuallen W, Kopia GA, Papandreou G, Narayan P et al. Twenty-eight-day efficacy and phamacokinetics of the sirolimus-eluting stent. Coron Artery Dis 2002;13:183-188. (Pubitemid 34747967)
19. Schwartz RS, Huber KC, Murphy JG, Edwards WD, Camrud AR, Vlietstra RE et al. Restenosis and the proportional neointimal response to coronary artery injury: results in a porcine model. J Am Coll Cardiol 1992;19:267-274.
20. Kornowski R, Hong MK, Tio FO, Bramwell O, Wu H, Leon MB. In-stent restenosis: contributions of inflammatory responses and arterial injury to neointimal hyperplasia. J Am Coll Cardiol 1998;31:224-230. (Pubitemid 28064746)
21. Asahara T, Bauters C, Pastore C, Isner JM. Local delivery of vascular endothelial growth factor accelerates reendothelialization and attenuates intimal hyperplasia in balloon-injured rat carotid artery. Circulation 1995;91:2793-2801.
22. Ma X, Hibbert B, White D, Seymour R, Whitman SC, O'Brien ER. Contribution of recipient-derived cells in allograft neointima formation and the response to stent implantation. PLoS ONE 2008;3:e1894. (Pubitemid 351943728)
23. De Leon H, Ollerenshaw JD, Griendling KK, Wilcox JN. Adventitial cells do not contribute to neointimal mass after balloon angioplasty of the rat common carotid artery. Circulation 2001;104:1591-1593. (Pubitemid 32947518)
24. Jabs A, Moncada GA, Nichols CE, Waller EK, Wilcox JN. Peripheral blood mono-nuclear cells acquire myofibroblast characteristics in granulation tissue. J Vasc Res 2005;42:174-180. (Pubitemid 41201983)
25. Ingram DA, Mead LE, Tanaka H, Meade V, Fenoglio A, Mortell K et al. Identification of a novel hierarchy of endothelial progenitor cells using human peripheral and umbilical cord blood. Blood 2004;104:2752-2760. (Pubitemid 39434958)
26. Yoder MC, Mead LE, Prater D, Krier TR, Mroueh KN, Li F et al. Redefining endothelial progenitor cells via clonal analysis and hematopoietic stem/progenitor cell principals. Blood 2007;109:1801-1809. (Pubitemid 46348173)
27. Colombo A, Corbett SJ. Drug-eluting stent thrombosis: increasingly recognized but too frequently overemphasized. J Am Coll Cardiol 2006;48:203-205.
28. Hill JM, Zalos G, Halcox JP, Schenke WH, Waclawiw MA, Quyyumi AA et al. Circulating endothelial progenitor cells, vascular function, and cardiovascular risk. N Engl J Med 2003;348:593-600. (Pubitemid 36204953)
29. Seeger FH, Tonn T, Krzossok N, Zeiher AM, Dimmeler S. Cell isolation procedures matter: a comparison of different isolation protocols of bone marrow mononuclear cells used for cell therapy in patients with acute myocardial infarction. Eur Heart J 2007;28:766-772. (Pubitemid 46439231)
30. Aoki J, Serruys PW, van BH, Ong AT, McFadden EP, Sianos G et al. Endothelial progenitor cell capture by stents coated with antibody against CD34: the HEALING-FIM (Healthy Endothelial Accelerated Lining Inhibits Neointimal Growth-First In Man) Registry. J Am Coll Cardiol 2005;45:1574-1579. (Pubitemid 40704488)
31. Luscher TF, Steffel J, Eberli FR, Joner M, Nakazawa G, Tanner FC et al. Drug-eluting stent and coronary thrombosis: biological mechanisms and clinical implications. Circulation 2007;115:1051-1058. (Pubitemid 46328299)
32. Virmani R, Guagliumi G, Farb A, Musumeci G, Grieco N, Motta T et al. Localized hypersensitivity and late coronary thrombosis secondary to a sirolimus-eluting stent: should we be cautious? Circulation 2004;109:701-705.
33. Finn AV, Kolodgie FD, Harnek J, Guerrero LJ, Acampado E, Tefera K et al. Differential response of delayed healing and persistent inflammation at sites of overlapping sirolimus-or paclitaxel-eluting stents. Circulation 2005;112:270-278. (Pubitemid 40982311)
34. Guagliumi G, Farb A, Musumeci G, Valsecchi O, Tespili M, Motta T et al. Images in cardiovascular medicine. Sirolimus-eluting stent implanted in human coronary artery for 16 months: pathological findings. Circulation 2003;107:1340-1341.
35. Butzal M, Loges S, Schweizer M, Fischer U, Gehling UM, Hossfeld DK et al. Rapamycin inhibits proliferation and differentiation of human endothelial progenitor cells in vitro. Exp Cell Res 2004;300:65-71. (Pubitemid 39286218)
36. Chen TG, Chen JZ, Wang XX. Effects of rapamycin on number activity and eNOS of endothelial progenitor cells from peripheral blood. Cell Prolif 2006;39:117-125.
37. Farb A, Sangiorgi G, Carter AJ, Walley VM, Edwards WD, Schwartz RS et al. Pathology of acute and chronic coronary stenting in humans. Circulation 1999;99:44-52. (Pubitemid 29035956)
38. Grewe PH, Deneke T, Machraoui A, Barmeyer J, Muller K-P. Acute and chronic tissue response to coronary stent implantation: pathologic findings in human specimen. J Am Coll Cardiol 2000;35:157-163. (Pubitemid 30061274)
39. Finn AV, Nakazawa G, Joner M, Kolodgie FD, Mont EK, Gold HK et al. Vascular responses to drug eluting stents: importance of delayed healing. Arterioscler Thromb Vasc Biol 2007;27:1500-1510. (Pubitemid 46986103)
40. Ma X, O'Brien ER. Antagonism of the alpha4 integrin subunit attenuates the acute inflammatory response to stent implantation yet is insufficient to prevent late intimal formation. J Leukoc Biol 2004;75:1016-1021. (Pubitemid 38720642)
41. Park KW, Yang HM, Youn SW, Yang HJ, Chae IH, Oh BH et al. Constitutively active glycogen synthase kinase-3beta gene transfer sustains apoptosis, inhibits proliferation of vascular smooth muscle cells, and reduces neointima formation after balloon injury in rats. Arterioscler Thromb Vasc Biol 2003;23:1364-1369.
42. Lee CS, Kwon YW, Yang HM, Kim SH, Kim TY, Hur J et al. New mechanism of rosi-glitazone to reduce neointimal hyperplasia: activation of glycogen synthase kinase-3 beta followed by inhibition of MMP-9. Arterioscler Thromb Vasc Biol 2009;29:472-479.
43. O'Brien ER, Alpers CE, Stewart DK, Ferguson M, Tran N, Gordon D et al. Proliferation in primary and restenotic coronary atherectomy tissue: implications for anti-proliferative therapy. Circ Res 1993;73:223-231. (Pubitemid 23212102)
44. Glover C, Ma X, Chen YX, Miller H, Veinot J, Labinaz M et al. Human in-stent rest-enosis tissue obtained by means of coronary atherectomy consists of an abundant proteoglycan matrix with a paucity of cell proliferation. Am Heart J 2002;144: 702-709.